J&J MedTech's Next Growth Phase
Johnson & Johnson MedTech CEO Tim Schmid announced the company's entry into its next growth phase, focusing on surgical robotics, cardiovascular technologies, and targeted portfolio management.
- Key areas of focus: cardiovascular, surgery, and vision
- Preparing to separate orthopedics business into a standalone company
"leaning in" to high-growth areas
J&J MedTech reported $8.4 billion in revenue last quarter, with 5.6% year-over-year growth, driven by strong performance in cardiovascular technologies and steady gains in wound closure, surgical instrumentation, and vision care.
Author's summary: J&J MedTech enters next growth phase with focus on robotics and portfolio management.
More News
- broadcaster — definition and usage
- Zarah Sultana MP Twitter Bio
- Construction activity shrank 'at fastest pace since COVID' ahead of budget
- Kim Kardashian’s brain scan shows ‘low activity’ and holes. I’m a brain expert and I have questions
- UK politics: Your Party's Sultana suggests electoral alliances
- Zarah Sultana triumphs at Your Party’s first conference
- Australian Open as it happened: Great Dane Neergaard-Petersen beats Smith after last-putt heartbreaker
- New party founded by Corbyn adopts Your Party as name
- Nigel Farage hits out at broadcasters as racism allegations continue to mount
- Wisconsin GOP hopeful warns of fraud lessons from Minnesota